OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma

This is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in patients with recurrent glioblastoma and newly diagnosed MGMT-unmethylated glioblastoma who are eligible to receive radiation therapy following surgery, and to establish the recommended Phase 2 dose.

NCT Number	NCT07739017
Lead Sponsor	Olivia Newton-John Cancer Research Institute Collaborators: Curtana Pharmaceuticals, Inc.
Conditions	Recurrent Glioblastoma, Newly Diagnosed MGMT Unmethylated Glioblastoma
Enrollment	54 participants
Start Date	2026-12
Primary Completion	2028-06 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-31